21 results about "Lowered intraocular pressure" patented technology

A glaucoma treatment apparatus including an imaging device capable of imaging the anterior segment of the eye, a treatment laser, an algorithm programmed to determine a location and a cross sectional area of a treatment based on a customized anatomy of the anterior segment of the eye including the trabecular meshwork (TM), the Schlemm's Canal (SC) and collector channels (CCS), obtained from pre-operative images of the anterior segment of the eye, a pre-operative intraocular pressure (IOP) level and a target IOP reduction as an inputs, and a processor configured to actuate the apparatus to create an outflow channel with a cross-sectional area and location or multiple outflow channels with multiple cross-sectional areas and locations from the anterior chamber (AC) to the SC across the TM, as determined by the algorithm to achieve the target intraocular pressure (IOP) reduction. Also disclosed is a method of reducing intraocular pressure in an eye.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

The purpose of the present invention is to discover an eye drop capable of effectively lowering intraocular pressure even at night, especially during night sleep, in patients with glaucoma or ocular hypertension.　The present invention is an eye drop for lowering intraocular pressure during night sleep in patients suffering from glaucoma or ocular hypertension, the eye drop containing sepetaprost at a concentration of 0.002% (w / v) as an active ingredient.

This invention relates to the field of traditional Chinese medicine (TCM) technology. The invention provides a TCM composition for treating glaucoma and its preparation method, comprising the following components in parts by weight: 18-28 parts of Cassia seed, 12-18 parts of Lycium fruit, 12-18 parts of Eriocaulon buergerianum, 10-15 parts of vinegar-processed Cyperus rotundus, 10-15 parts of mulberry leaf, 10-15 parts of Ligusticum chuanxiong, 8-12 parts of Polyporus umbellatus, 5-8 parts of Pueraria lobata, 5-8 parts of Akebia quinata, 3-5 parts of Curcuma longa, 3-5 parts of Indigo naturalis, and 2-4 parts of prepared licorice root. The TCM composition of this invention has a strong effect in lowering intraocular pressure, improving retinal blood supply, and preventing optic nerve atrophy caused by glaucoma; simultaneously, the processing method maximizes the retention of the active pharmaceutical ingredients. Furthermore, the technical solution of this invention achieves a dual improvement in efficacy and safety, and also reduces the recurrence rate and side effects.

This disclosure relates to a shunt for fibrous encapsulation of glaucoma patients which lowers intraocular pressure by penetrating a fibrous encapsulation of a bleb formed between a sclera and a conjunctiva and draining aqueous humor within the bleb to subconjunctival.

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.

The invention relates to the technical field of biology, in particular to a method for constructing an intraocular hypertension model through anterior chamber injection of GMA-EPL-LAP hydrogel. The construction method of the chronic intraocular hypertension animal model is high in stability and more suitable for long-term observation and research, the problem that the model is poor in stability is solved, the intraocular hypertension maintaining time is greatly prolonged, and the risk that intraocular pressure is increased due to repeated injection after the intraocular pressure is reduced is reduced; operation is easy and convenient, complex instruments and technologies are not needed, and harm to animals can be reduced; the application range is wide; and the hydrogel can be gradually degraded and absorbed in vivo, so that the potential safety hazard caused by long-term implantation of the hydrogel in vivo is avoided.

The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals

A method for treating glaucoma and a method for lowering intraocular pressure of the invention are excellent methods because the safety is high, ingestion can be carried out on a daily basis, and the methods only involves administering green chiretta.

A device for lowering intraocular pressure is disclosed herein. In an example, the device includes a continuous plate structure that enables aqueous humor to flow from a first end to a second end. The first end has a maximum width that is narrower than a maximum width of the second end. The continuous plate structure includes an uppermost surface opposite a lowermost surface, the uppermost surface including a plurality of open cells. The continuous plate structure also includes a fluid pathway including a plurality of open channels formed into the lowermost surface. The open channels are configured in an intersecting grid pattern extending from the first end to the second end of the continuous plate structure. The open channels provide for the flow of aqueous humor, thereby reducing intraocular pressure.

The present disclosure relates to colloidal drug aggregates (CDAs) that are further embedded in hydrogels for sustained local delivery. Preferred drugs include beta-blocker prodrugs and ROCK inhibitors for use in treating glaucoma. In particularly preferred embodiments, the CDAs comprise prodrugs of timolol or netarsudil in combination with phospholipid stabilizers. Preferred hydrogels include hyaluronan crosslinked using an oxime bond.

A shunt 10 for treating glaucoma by lowering intraocular pressure in an eye of a patient, comprises an elongate duct 12 having a lumen 15 for diverting aqueous humor from a chamber of the eye, and a removable intraluminal filament 24 received in the lumen. A distal end of the duct is implantable in the anterior chamber and an opposite proximal end is implantable in a channel formed in the sclera adjacent the anterior chamber. The intraluminal filament 24 emanates from the proximal end of the elongate duct, for regulating resistance to fluid flow through the lumen. The intraluminal filament 24 has a number of enlarged fixation formations 26 located within the conjunctival / tenon's complex for resisting migration of the intraluminal filament following implantation. The intraluminal filament can be partially or completely withdrawn from the elongate duct in order to reduce resistance to fluid flow and further regulate intraocular pressure following implantation of the shunt.

Disclosed herein is a device, system and method configured to safely regulate aqueous outflow in a patient's eye while dynamically maintaining a normal range of intraocular pressure. An example thin-film implant comprises a plurality of topographical features implemented on first and second surfaces of the implant. The topographical features include a network of interconnected channels configured to direct aqueous humor in a patient's eye to flow through and across the surfaces of the thin-film implant for lowering intraocular pressure. Multiple control structures are implemented on one or more selected locations of the first and second surfaces to regulate the aqueous humor in the patient's eye.

The present disclosure relates to a drug for preventing and / or treating glaucoma. Specifically, provided in the present disclosure is the use of an adenosine A2A receptor antagonist in the treatment and prevention of glaucoma. The treatment and prevention include, but are not limited to, inhibiting aqueous humor production in non-pigmented epithelial cells of the ciliary body, reducing elevated intraocular pressure caused by the obstruction of aqueous humor outflow due to fibrosis and thickening of the trabecular meshwork, improving the fluidity of aqueous humor in the eye, inhibiting pathological changes in the trabecular meshwork, and achieving a protective effect on retinal cells. Additionally, the drug of the present disclosure may also help to reduce the problem of drug tolerance in the treatment of glaucoma, can lower intraocular pressure in glaucoma patients and provide a protective effect on optic nerves, and provides a more effective strategy for long-term treatment.

Devices and methods for lowering intraocular pressure are disclosed, including applying a cooling device to a surface of the eye of the patient, the cooling device including a housing, a contact element, and a cold slurry, the contact element is at or below a certain temperature when applied to the surface of the eye, the contact element is applied to the eye for period of time, and the application of the cooling device causes a lowering of the intraocular pressure of the eye.

The utility model discloses a ciliary muscle stimulator for adjusting intraocular pressure. The ciliary muscle stimulator comprises an atrial angle mirror, an electrode slice and an electrode stimulator, the chamber angle lens comprises a corneal contact lens making contact with the cornea, the corneal contact lens is provided with an expansion edge, the expansion edge extends to the limbus of the cornea, a groove is formed in the surface of the expansion edge, and the electrode slice is placed in the groove and connected with the electrode stimulator. The device can quickly break pupil block / ciliary ring block, so that the intraocular pressure is reduced to a safe range.

A device for lowering intraocular pressure is disclosed herein. In an example, the device includes a plate structure that enables aqueous humor to flow from a first end to a second end. The plate structure includes a first exposed surface opposite a second exposed surface. The first exposed surface includes a plurality of open cells. The second exposed surface includes a fluid pathway comprising a plurality of open channels. The plurality of open channels is configured in an intersecting grid pattern extending from the first end to the second end of the plate structure. Each of the plurality of open channels includes a channel ceiling, at least one channel wall, and an open-end located opposite the respective channel ceiling, thereby forming an open volume between the respective channel wall and the respective channel ceiling accessible through the respective open-end. The plate structure reduces intraocular pressure within the eye.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

To provide a composition for use in a method of lowering intraocular pressure in a patient.SOLUTION: The composition of the present disclosure includes brimonidine or a pharmaceutically acceptable salt thereof, and brinzolamide or a pharmaceutically acceptable salt thereof. The above method includes: a) a step of confirming whether an effect by other glaucoma remedy is sufficient or insufficient, for a patient; b) a step of measuring an intraocular pressure of the patient before administration of a remedy; c) a step of selecting a patient in which, the effect of other glaucoma remedy is insufficient and the intraocular pressure before administration of the remedy is less than 20 mmHg; and d) a step of administering the composition to the selected patient. The patient is a patient who has glaucoma or ocular hypertension and receives other glaucoma remedy.SELECTED DRAWING: None

This invention relates to the field of biotechnology and discloses a method for screening drugs capable of preventing and / or treating posterior segment diseases of the eye. The method includes: first, decompressing the anterior chamber of an experimental animal; then, pre-establishing a "perforation-closure" channel in the sclera of the experimental animal; next, injecting the drug to be screened into the suprachoroidal space of the experimental animal through the "perforation-closure" channel in the sclera; and finally, evaluating the effectiveness of the drug in preventing and / or treating posterior segment diseases based on changes in the eye condition of the experimental animal. This invention reduces the incidence of ocular surface inflammation and improves safety by lowering intraocular pressure and creating a pre-closed scleral incision to prevent backflow of the injected AAV vector; it also provides a broader expression range and longer duration of action. Studies have shown that injecting shRNA targeting the TGF-β2 gene using the method of this invention inhibits myopia progression in a guinea pig model. The method provided by this invention is beneficial for screening gene therapy drugs related to posterior segment diseases.

Disclosed herein is a device, system and method configured to safely regulate aqueous outflow in a patient's eye while dynamically maintaining a normal range of intraocular pressure. An example thin-film implant comprises a plurality of topographical features implemented on first and second surfaces of the implant. The topographical features include a network of interconnected channels configured to direct aqueous humor in a patient's eye to flow through and across the surfaces of the thin-film implant for lowering intraocular pressure. Multiple control structures are implemented on one or more selected locations of the first and second surfaces to regulate the aqueous humor in the patient's eye.